BSX
Stock Details
BSX is Boston Scientific Corporation's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 41.80$. Average daily volumn in 3 months 7.06M. Market cap 64.51B
Stock symbol : BSX. Exchange : NYSE. Currency : USD Lastest price : 45.04$. Total volume : 3.25M. Market state REGULAR Click reload if you want to check the lastest price on market!!!
Boston Scientific Corporation (BSX)
Last Price
45.04$Change
-0.38Volume
3.25M
| Previous Close | 45.42 |
| Open | 45.31 |
| Day Range | 44.81-45.53 |
| Bid | 44.92 x 2.9k |
| Ask | 44.93 x 1.3k |
| Volume | 3.25M |
| Average Volume | 7.06M |
| Market Cap | 64.51B |
| Beta | 0.86 |
| 52 Week Range | 34.98-47.50 |
| Trailing P/E | 104.74 |
| Foward P/E | 23.22 |
| Dividend (Yield %) | N/A |
| Ex-Dividend Date | N/A |
Financial Details
Organization
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable c... ardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Market Cap:
64.51BRevenue:
11.89BTotal Assets:
32.23BTotal Cash:
1.93B
News about "Boston Scientific Corporation"
Boston Scientific's (BSX) New Buyout to Expand its Portfolio
Source from : Nasdaq - 6 days ago
The transaction, which is expected to be completed in the first half of 2023, subject to the satisfaction of customary closing conditions, is likely to have an immaterial impact on Boston Scientific's ...See details»
Boston Scientific shelling out $615M for Apollo Endosurgery
Source from : The Business Journals - 6 days ago
The Boston-area medical device maker (NYSE: BSX) is set to buy Apollo Endosurgery Inc. (Nasdaq: APEN) at $10 a share, about a 60% premium over where it had been trading over the past week. By market ...See details»
Why Have Boston Scientific Corporation (NYSE: BSX) Shares Declined So Much?
Source from : stocksregister - 7 days ago
Boston Scientific Corporation (NYSE:BSX) price is hovering higher on Tuesday, November 29, jumping 1.31% above its previous close. A look at today’s price movement shows that the recent level at last ...See details»
Boston Scientific to buy Apollo Endosurgery for $417 million
Source from : Reuters - 7 days ago
Nov 29 (Reuters) - Boston Scientific Corporation (BSX.N) said on Tuesday it will buy medical technology firm Apollo Endosurgery Inc (APEN.O) for $417 million to expand its portfolio of gastric ...See details»
Boston Scientific shells out $615M for gastro device firm
Source from : The Business Journals - 6 days ago
Boston Scientific Corp. is paying $615 million to acquire an Austin, Texas–based maker of devices for gastroenterological surgeries. The Marlborough medical device maker (NYSE: BSX) is set to ...See details»
Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham
Source from : MarketWatch on MSN - 7 days ago
Boston Scientific Corp.'s $615 million acquisition of Apollo Endosurgery Inc. announced earlier is complementary to the former's endoscopy franchise, as it leverages its gastroenterologist call point ...See details»
Boston Scientific (BSX) Posts Positive Post-Market Study Data
Source from : Nasdaq - 8 days ago
Boston Scientific Corporation BSX recently announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study, which evaluated the performance of the ACURATE neo2 Aortic ...See details»
Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.
Source from : Yahoo - 7 days ago
Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc. (Nasdaq: APEN) for a cash ...See details»
Boston Scientific to acquire Apollo Endosurgery for $615 million in cash
Source from : MarketWatch on MSN - 7 days ago
Boston Scientific Corp. said Tuesday it has agreed to acquire Apollo Endosurgery Inc. for $10 a share, or about $615 million in cash. The news sent Apollo's stock, which closed Monday at $6, up 61% in ...See details»
Apollo Endosurgery to be Acquired by Boston Scientific
Source from : Yahoo Finance - 7 days ago
announced today it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation ("Boston Scientific"), a global medical technology leader, in an all-cash ...See details»
“The Buzz” Show: Apollo Endosurgery (NASDAQ: APEN) to be Acquired by Boston Scientific
Source from : Financial Buzz - 7 days ago
Featuring Our Corporate News Recap on “ Apollo Endosurgery to be Acquired by Boston Scientific for USD 615 million in cash ” Apollo ...See details»
Boston Scientific to acquire Apollo Endosurgery in $615M deal
Source from : Becker's ASC - 7 days ago
Boston Scientific has entered into a definitive agreement to acquire gastrointestinal device company Apollo Endosurgery. The deal reflects an enterprise value of about $615 million, according to a Nov ...See details»
Boston Scientific to acquire MedTech firm Apollo Endosurgery for $10/ share
Source from : Seeking Alpha - 7 days ago
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...See details»
Boston Scientific Corp.
Source from : U.S. News & World Report - 13 days ago
Financial advisors can help their clients by planning ahead and taking advantage of the higher retirement contribution limits in 2023.See details»